Movement Alert｜RemeGen Rises 6.93% in Regular Trading, Innovative Drug Payment Reform Catalyzes Biotech Sector Rally

Market Focus

8 hours ago

On July 3, RemeGen rose 6.93% in regular trading, trading at HK$84.25/share, with turnover of HK$168 million.

On the news front, the innovative drug sector extended its strength as dual-directory negotiations between basic medical insurance and commercial insurance entered a substantive stage, continuously catalyzing sector sentiment. A total of 557 drugs passed the basic medical insurance directory preliminary review, while 54 passed the commercial insurance innovative drug directory preliminary review. Combined with the implementation of an 8-year price protection mechanism, the payment channel has shifted toward a dual-track system of medical insurance plus commercial insurance, further expanding the commercialization potential for innovative drugs.

CITIC Construction Investment noted its optimistic outlook on innovative drug enterprises' medical insurance access and incremental commercial insurance opportunities, reinforcing the policy tailwind. Sector peers also rallied broadly, with 3SBio up 5.07%, BeiGene up 4.81%, and Akeso up 4.06%, reflecting strong industry-wide beta momentum driving the rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1139988130"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139988130\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139988130?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139988130","market":"hk","top_or_hot":-1,"title":"Movement Alert｜RemeGen Rises 6.93% in Regular Trading, Innovative Drug Payment Reform Catalyzes Biotech Sector Rally","media":"Market Focus","content":"<p><p>On July 3, RemeGen rose 6.93% in regular trading, trading at HK$84.25/share, with turnover of HK$168 million.</p><p>On the news front, the innovative drug sector extended its strength as dual-directory negotiations between basic medical insurance and commercial insurance entered a substantive stage, continuously catalyzing sector sentiment. A total of 557 drugs passed the basic medical insurance directory preliminary review, while 54 passed the commercial insurance innovative drug directory preliminary review. Combined with the implementation of an 8-year price protection mechanism, the payment channel has shifted toward a dual-track system of medical insurance plus commercial insurance, further expanding the commercialization potential for innovative drugs.</p><p>CITIC Construction Investment noted its optimistic outlook on innovative drug enterprises' medical insurance access and incremental commercial insurance opportunities, reinforcing the policy tailwind. Sector peers also rallied broadly, with 3SBio up 5.07%, BeiGene up 4.81%, and Akeso up 4.06%, reflecting strong industry-wide beta momentum driving the rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Rises 6.93% in Regular Trading, Innovative Drug Payment Reform Catalyzes Biotech Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Rises 6.93% in Regular Trading, Innovative Drug Payment Reform Catalyzes Biotech Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-03 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 3, RemeGen rose 6.93% in regular trading, trading at HK$84.25/share, with turnover of HK$168 million.</p><p>On the news front, the innovative drug sector extended its strength as dual-directory negotiations between basic medical insurance and commercial insurance entered a substantive stage, continuously catalyzing sector sentiment. A total of 557 drugs passed the basic medical insurance directory preliminary review, while 54 passed the commercial insurance innovative drug directory preliminary review. Combined with the implementation of an 8-year price protection mechanism, the payment channel has shifted toward a dual-track system of medical insurance plus commercial insurance, further expanding the commercialization potential for innovative drugs.</p><p>CITIC Construction Investment noted its optimistic outlook on innovative drug enterprises' medical insurance access and incremental commercial insurance opportunities, reinforcing the policy tailwind. Sector peers also rallied broadly, with 3SBio up 5.07%, BeiGene up 4.81%, and Akeso up 4.06%, reflecting strong industry-wide beta momentum driving the rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1139988130","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139988130","pubTimestamp":1783043396,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 3, RemeGen rose 6.93% in regular trading, trading at HK$84.25/share, with turnover of HK$168 million.On the news front, the innovative drug sector extended its strength as dual-directory...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"动感快讯|RemeGen常规交易涨6.93%创新药支付改革催化生物科技板块涨势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On July 3, RemeGen rose 6.93% in regular trading, trading at HK$84.25/share, with turnover of HK$168 million.On the news front, the innovative drug sector extended its strength as dual-directory negotiations between basic medical insurance and commercial insurance entered a substantive stage, continuously catalyzing sector sentiment. A total of 557 drugs passed the basic medical insurance directory preliminary review, while 54 passed the commercial insurance innovative drug directory preliminary review. Combined with the implementation of an 8-year price protection mechanism, the payment channel has shifted toward a dual-track system of medical insurance plus commercial insurance, further expanding the commercialization potential for innovative drugs.CITIC Construction Investment noted its optimistic outlook on innovative drug enterprises' medical insurance access and incremental commercial insurance opportunities, reinforcing the policy tailwind. Sector peers also rallied broadly, with 3SBio up 5.07%, BeiGene up 4.81%, and Akeso up 4.06%, reflecting strong industry-wide beta momentum driving the rebound.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}